Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. - Wikidata - awgldk - TriplyDB

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

http://www.wikidata.org/entity/Q33800427

about

Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.Platelet count kinetics following interruption of antiretroviral treatment.Paroxysmal nocturnal haemoglobinuria. Experience over a 10 years period.CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria.Thrombotic complications in paroxysmal nocturnal haemoglobinuria: a literature review Successful Treatment of Ascites using a Denver® Peritoneovenous Shunt in a Patient with Paroxysmal Nocturnal Hemoglobinuria and Budd-Chiari syndrome.Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.Management of paroxysmal nocturnal haemoglobinuria: a personal view.Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria.Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.Hematological disorders and pulmonary hypertension.Extracellular vesicles in renal disease.Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.Recurrent and progressive abdominal pain and enteritis in a Japanese patient with paroxysmal nocturnal hemoglobinuria.Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria.Paroxysmal nocturnal hemoglobinuria and eculizumab.Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.Polymorphism of the ABO gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria.Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways.Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria.Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation

P2860

Q26740877-438C177E-4C1A-4090-A00C-2E0B38CD73B0 Q26766624-C1F4714B-D25D-4FD7-BB2D-3B5B0B7C7A03 Q27021748-FBEE18DD-F768-4D4F-A7F4-31B709C88EC0 Q27027097-B984554F-E2E1-4BDC-97CB-3AFC9C5E4069 Q33398524-E5B34619-8616-4C3F-85A3-B9AD6CC3A0D5 Q33403565-D9C931FA-D01E-42D8-8174-5389D08E32AD Q33411290-91AB71E3-2698-4060-8580-3E676CAB82DA Q33690900-AA1F1F90-3562-4786-B487-AE2803BFD98F Q34626253-65BF9EF7-FB68-4E25-A68D-119FCBE249A6 Q35093962-289A6F70-E021-426D-8E2F-57EDFDBEBF92 Q35252156-EEE313AD-48BC-43AB-B13D-793C36606128 Q36366577-014ABC87-847C-46AD-88F5-BADE3ACE18C7 Q36393498-373E18DD-A49F-414D-84EF-81B86E72C62B Q37414362-FCF533F7-6325-41A0-8131-7830047C3CB5 Q37724607-0274637C-F41F-418A-BFAE-F583544B3090 Q37868639-2AA8C32B-BC99-48C4-9130-22EFFFE4E494 Q37924893-583D042C-C1A5-4D15-BABD-94DE9124CA92 Q37955206-F14C6486-F66B-4835-A59F-01954F01C1E8 Q37956407-8779A6C0-A7B0-4ECA-8423-C7407FF21E62 Q38156229-DEF7FC09-6FC9-49D0-8118-20F6CD255047 Q38370916-018E2453-C96D-44EE-997A-D9D75126C550 Q39077582-2FE74661-5C2B-4798-8539-5B241756558B Q39453434-DBBEDC6B-744C-46AA-BDAD-FB7A979D131B Q39566121-23B0B759-50E6-442C-8EE3-6CF08C869775 Q41263906-5B10051A-FD97-4E86-94C9-FA886DE1AC83 Q41949334-1450EBA2-1692-4AAF-9F6C-7819B555E957 Q42783308-D4EE00DC-8B9A-49F2-9D65-9707BE784460 Q42832542-9009B740-50C0-475A-A6BB-6966BBFD1EDC Q44681539-FB432DFA-B598-4311-8261-C2388B0A3881 Q46683290-49A9FFFF-31BF-41F1-A5C9-807DBB5E2C15 Q48371887-76D75C58-444F-4AF3-BE4F-E79532C0A93A Q50548486-1B641369-AD8D-409C-923A-571CC3A14CF2 Q57197889-390FBC6A-86F2-4873-87CA-182297C510F6

P2860

Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

http://www.wikidata.org/entity/Q33800427

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@ast

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@en

type

label

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@ast

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@en

prefLabel

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@ast

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@en

P1433

Q33800427-2BF4EEA3-7570-4D16-8B3F-A1D809607453

P1476

Q33800427-56131220-3F0B-45C6-A7C8-D6E076996A6D

P2093

Q33800427-0E0B0E2B-79EC-4361-9CDD-4B2D6657CA6B

Q33800427-1E1D3A29-080D-46EF-8875-E2317369B6F8

Q33800427-68E306EE-B98E-4F3B-96AC-C0D2E5CE4309

Q33800427-6E4DD279-2954-4E6E-AFA3-DAEB63912E67

Q33800427-6F55BB97-051B-4A3C-8162-78293A8A82F0

Q33800427-70E7DAD5-4A55-443C-BC26-C2427E8A76F4

Q33800427-75D1F116-E5BB-446A-98B6-E706F6693D07

Q33800427-A7205684-DE9A-4938-81CD-37DE3B3CC07B

Q33800427-D9254B1F-F2F5-461C-96FD-7544184E850D

P2860

Q33800427-18F0F70C-B568-4659-97AF-1650A4558ABE

Q33800427-205E09B9-63EF-4A32-B23C-471F3A5DE5AE

Q33800427-25606A7A-F0A2-41C9-97B8-5B0765E62B93

Q33800427-2966D9C3-A29B-4BA3-BF54-0D535D43D610

Q33800427-2A333E7B-4220-472E-95CA-78F2DDA2CD96

Q33800427-32367EFE-0FFA-4E36-A54C-D1B536468F01

Q33800427-36060FCC-9C81-4DD0-9A6F-C20BD0364CCC

Q33800427-42C03129-5892-4064-91F7-6617D73F2826

Q33800427-4CC92B7C-6B72-4C78-947E-EFD847C116DE

Q33800427-4CF768B3-85FE-4D26-9A54-3DB723D235D5

P304

Q33800427-F5534EFB-C074-4378-AE5C-5746868A0780

P31

Q33800427-CB45F1E0-C39B-4D4D-A18C-6DEC09012357

P356

Q33800427-E87DB1B0-1EB5-4A60-A579-3EC2E0416606

P433

Q33800427-D6234E5A-9415-4522-82D4-2D0AB105F837

P478

Q33800427-E632FB4F-2C21-4C11-AD69-0113DC5A884C

P50

Q33800427-13F2B0C3-CCE6-4D84-B908-FA269E6A7426

Q33800427-35012D79-7688-4836-A0E9-12A56B537BC1

P577

Q33800427-8092C816-A1F1-43F2-A0A3-A9D6E47BA429

P5875

Q33800427-D7C8077E-5D19-403B-81ED-5302275644A3

P698

Q33800427-7C7B083B-7BCB-4DDE-8E3F-7D1E9057FDEA

P921

Q33800427-8452626E-1E19-44FF-ACE8-82A4AB3C9097

P932

Q33800427-2C164F4D-4252-4607-AAB7-3774AA067365

P356

HAEMATOL.2009.016121

P1433

P1476

Evaluation of hemostasis and e ...... obinuria receiving eculizumab.

@en

P2093

Anne-Marie Fischer

http://www.w3.org/2001/XMLSchema#string

Arnaud Duval

http://www.w3.org/2001/XMLSchema#string

Celso Arrais Rodrigues

http://www.w3.org/2001/XMLSchema#string

Dominique Helley

http://www.w3.org/2001/XMLSchema#string

French Society of Hematology

http://www.w3.org/2001/XMLSchema#string

Isabelle Galy-Fauroux

http://www.w3.org/2001/XMLSchema#string

Jean-François Schved

http://www.w3.org/2001/XMLSchema#string

Jeanne Matheron

http://www.w3.org/2001/XMLSchema#string

Raphaël Porcher

http://www.w3.org/2001/XMLSchema#string

P2860

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.

Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link.

Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

Differential regulation of endothelial cell activation by complement and interleukin 1alpha

Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients

The pathophysiology of paroxysmal nocturnal hemoglobinuria.

P304

574-581

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2009.016121

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Régis Peffault de Latour

P577

2010-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41040727

http://www.w3.org/2001/XMLSchema#string

P698

20081060

http://www.w3.org/2001/XMLSchema#string

P921

P932

2857186

http://www.w3.org/2001/XMLSchema#string